Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00646906 · ClinicalTrials.gov registry record · NA
Mechanisms of Action of Acetaminophen
A NA study of Myocardial Infarction and Arthritis, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT00646906: Completed NA study of Myocardial Infarction and Arthritis, sponsored by University of Pennsylvania.
NCT00646906 is a NA study of Myocardial Infarction and Arthritis that has completed, run by University of Pennsylvania. The registered enrollment target is 55 participants, below the 4,681-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00646906, a NA study of Myocardial Infarction and Arthritis, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study investigates whether the ability of aspirin to reduce the risk of heart attacks may be diminished by the administration of acetaminophen. Patients who have heart disease are often prescribed aspirin because of its unique ability to permanently prevent platelets from aggregating and forming a blood clot. Such blood clots cause heart attacks when they form in a blood vessel that supplies the heart with oxygen rich blood. Some of these same patients also take acetaminophen everyday for relief from arthritis pain. Higher doses of acetaminophen may also have the ability to prevent the platelets from clotting, however only temporarily. Therefore, this study evaluates whether the timing of the administration of acetaminophen (before or after aspirin) interferes with the permanent blood clotting effects of aspirin. The primary hypothesis is that acetaminophen given two hours before aspirin will antagonize the effects of aspirin, while reversing the order of administration will not.
Primary Outcome
Thromboxan B2 is a stable metabolite of thromboxane A2. Thromboxane B2 formation during clotting of whole blood (37 degrees Celsius, 1 hour) is reflective of the capacity of platelets to form thromboxane A2. Serum Thromboxane B2 was measured by radio-immuno assay. The quantity of interest was percent change from start (8:00 am on day 1) to finish (8:00 am on last day) of each crossover period in serum thromboxane B2. This was calculated as: 100%\*(value at start of period minus value at end of p
Conditions Studied
Interventions
- DRUG Aspirin First
- DRUG Aspirin Last
- DRUG Acetaminophen 1000 mg/d
- DRUG Acetaminophen 4000 mg/d
- DRUG Ibuprofen 800 mg/d
Study Locations (1)
Pennsylvania
- Hospital of The University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2004-06-02 |
| Est. Completion | 2012-01-24 |
| Phase | NA |
What the finished NCT00646906 record still lists
NCT00646906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 4,681-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 5 interventions - of which Aspirin First is the first listed.
NCT00646906 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00646906 about?
NCT00646906 is a clinical study titled "Mechanisms of Action of Acetaminophen". This research study investigates whether the ability of aspirin to reduce the risk of heart attacks may be diminished by the administration of acetaminophen. Patients who have heart disease are often prescribed aspirin because of its unique ability to permanently prevent platelets from aggregating a...
What is the current status of trial NCT00646906?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2004-06-02. Estimated completion is 2012-01-24.
What conditions does trial NCT00646906 study?
This clinical trial studies the following conditions: Myocardial Infarction, Arthritis.
What interventions are being tested in trial NCT00646906?
The interventions under investigation include: Aspirin First (DRUG), Aspirin Last (DRUG), Acetaminophen 1000 mg/d (DRUG), Acetaminophen 4000 mg/d (DRUG), Ibuprofen 800 mg/d (DRUG).
Who is sponsoring clinical trial NCT00646906?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00646906 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00646906's enrollment target sits among peer trials
55 57th of 64 higher than 8 of 64 other Myocardial Infarction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
Women's Heart Attack Research Program: Stress Ancillary Study
RECRUITING · NA
-
Cardiac Radioablation for VT
RECRUITING · NA
-
Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.
RECRUITING · NA
-
Reducing Blood Pressure in Patients With High Cardiovascular Risk
RECRUITING · NA
-
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI